Local BDNF Delivery to the Injured Cervical Spinal Cord using an Engineered Hydrogel Enhances Diaphragmatic Respiratory Function.

Biswaup Ghosh  
*Thomas Jefferson University*, biswarup.ghosh@jefferson.edu

Zhicheng Wang  
*Drexel University*

Jia Nong  
*Drexel University*

Mark W. Urban  
*Thomas Jefferson University*, mark.urban@jefferson.edu

Zhiling Zhang  
*Drexel University*

*See next page for additional authors*

**Let us know how access to this document benefits you**

Follow this and additional works at: [https://jdc.jefferson.edu/farberneursofp](https://jdc.jefferson.edu/farberneursofp)

Part of the [Neurosciences Commons](https://jdc.jefferson.edu/farberneursofp)

---

**Recommended Citation**

[https://jdc.jefferson.edu/farberneursofp/30](https://jdc.jefferson.edu/farberneursofp/30)
Authors
Biswarup Ghosh, Zhicheng Wang, Jia Nong, Mark W. Urban, Zhiling Zhang, Victoria A. Trovillion, Megan C. Wright, Yinghui Zhong, and Angelo C. Lepore
We developed an innovative biomaterial-based approach to repair the critical neural circuitry that controls diaphragm activation by locally delivering brain-derived neurotrophic factor (BDNF) to injured cervical spinal cord. BDNF can be used to restore respiratory function via a number of potential repair mechanisms; however, widespread BDNF biodistribution resulting from delivery methods such as systemic injection or lumbar puncture can lead to inefficient drug delivery and adverse side effects. As a viable alternative, we developed a novel hydrogel-based system loaded with polysaccharide-BDNF particles self-assembled by electrostatic interactions that can be safely implanted in the intrathecal space for achieving local BDNF delivery with controlled dosing and duration. Implantation of BDNF hydrogel after C4/C5 contusion-type spinal cord injury (SCI) in female rats robustly preserved diaphragm function, as assessed by in vivo recordings of compound muscle action potential and electromyography amplitudes. However, BDNF hydrogel did not decrease lesion size or degeneration of cervical motor neuron soma, suggesting that its therapeutic mechanism of action was not neuroprotection within spinal cord. Interestingly, BDNF hydrogel significantly preserved diaphragm innervation by phrenic motor neurons (PhMNs), as assessed by detailed neuromuscular junction morphological analysis and retrograde PhMN labeling from diaphragm using cholera toxin B. Furthermore, BDNF hydrogel enhanced the serotonergic axon innervation of PhMNs that plays an important role in modulating PhMN excitability. Our findings demonstrate that local BDNF hydrogel delivery is a robustly effective and safe strategy to restore diaphragm function after SCI. In addition, we demonstrate novel therapeutic mechanisms by which BDNF can repair respiratory neural circuitry.

**Key words:** biomaterial; contusion; diaphragm; phrenic motor neuron; respiratory; spinal cord injury

### Significance Statement

Respiratory compromise is a leading cause of morbidity and mortality following traumatic spinal cord injury (SCI). We used an innovative biomaterial-based drug delivery system in the form of a hydrogel that can be safely injected into the intrathecal space for achieving local delivery of brain-derived neurotrophic factor (BDNF) with controlled dosing and duration, while avoiding side effects associated with other delivery methods. In a clinically relevant rat model of cervical contusion-type SCI, BDNF hydrogel robustly and persistently improved diaphragmatic respiratory function by enhancing phrenic motor neuron (PhMN) innervation of the diaphragm neuromuscular junction and by increasing serotonergic innervation of PhMNs in ventral horn of the cervical spinal cord. These exciting findings demonstrate that local BDNF hydrogel delivery is a safe and robustly effective strategy to maintain respiratory function after cervical SCI.
to perform other important pulmonary tasks such as coughing (which can result in respiratory infection; Warren and Alilain, 2014). Importantly, cervical SCI represents greater than half of all human cases, in addition to often resulting in the most severe physical and psychological debilitation (Lane et al., 2008). Cervical trauma disrupts the critical neural circuitry that controls a number of respiratory muscles, in particular the diaphragm (Warren et al., 2014).

Diaphragm dysfunction plays a central role in respiratory compromise after cervical SCI

Compromised inspiratory breathing occurs in a significant percentage of SCI patients due to paralysis of the major inspiratory muscle, the diaphragm (but likely also via effects on other muscles; Strakowski et al., 2007). The diaphragm is innervated by phrenic motor neurons (PhMNs) located at cervical levels 3–5 (Lane et al., 2009). PhMN output is driven by descending premotor bulboospinal neurons in a brainstem nucleus called the rostral ventral respiratory group (rVRG; Zimmer et al., 2007). Cervical SCI results in diaphragmatic respiratory compromise due to (1) PhMN loss and consequent denervation at the diaphragm neuromuscular junction (NMJ), and (2) injury to descending bulboospinal respiratory axons and consequent silencing of spared PhMNs.

Brain-derived neurotrophic factor hydrogel delivered locally to cervical SCI is a clinically applicable approach to repair respiratory neural circuitry

We chose to deliver brain-derived neurotrophic factor (BDNF) as it can potentially repair rVRG–PhMN–diaphragm circuitry after cervical contusion via a number of therapeutic mechanisms, including the following: (1) reducing secondary degeneration of this neural circuit that occurs following initial trauma (Novikova et al., 2000); (2) promoting regrowth of injured rVRG axons and/or sprouting of spared rVRG fibers (Weishaupt et al., 2012); (3) acting as a guidance molecule to direct rVRG axon reinnervation of their appropriate PhMN targets (Weishaupt et al., 2012); (4) modulating PhMN properties such as dendritic morphology, intrinsic excitability, glutamate receptor expression profile (Gill et al., 2016), and activation in response to excitatory synaptic input (Dale-Nagle et al., 2010); (5) enhancing synaptic transmission at the diaphragm NMJ (Mantilla et al., 2004; Gransee et al., 2013); and (6) maintaining diaphragm NMJ innervation and/or stimulating morphological changes at the NMJ such as terminal sprouting of phrenic motor axons and reinnervation of denervated endplates (Pitts et al., 2006). We have attempted to harness the multifaceted therapeutic potential of BDNF to promote repair of the critical neural circuitry controlling diaphragm function. In this study, we have specifically assessed the ability of BDNF to modulate (1) diaphragm innervation by phrenic motor axons peripherally at the NMJ and (2) PhMN innervation by descending serotonergic input centrally within the ventral horn, given that they are both critical to diaphragm activation and that the effects of BDNF on these mechanisms have not been assessed in the context of respiratory circuitry after SCI. Importantly, a number of neuronal components of the rVRG–PhMN–diaphragm circuit express the tropomyosin-related kinase receptor subtype B (TrkB) receptor, including PhMNs (Mantilla et al., 2013, 2014a) and serotonergic raphe neurons (Goswami et al., 2010). We have also found that rVRG neurons express TrkB (B. Charsar and A. Lepore unpublished observations), suggesting that BDNF hydrogel could also act upon these neurons to induce, for example, plasticity within the cervical spinal cord such as the regrowth of injured rVRG axons and/or sprouting of spared rVRG fibers to increase descending bulboospinal input to the PhMN pool.

Hydrogel-based system allows for safe delivery of BDNF to cervical SCI

Both intrathecal injection of BDNF solution (Mantilla et al., 2013; Hernandez-Torres et al., 2017) and intraspinal transplantation of BDNF-expressing mesenchymal stem cells (Gransee et al., 2015) partially improve diaphragm muscle activity in rodent models of cervical SCI. Unlike the targeted local delivery achieved with our system, clinically used lumbar intrathecal injection can result in more widespread distribution, and strategies such as viral delivery and cell transplantation may result in persistent expression, which potentially reduces its efficacy. Previous studies have also reported that persistent, anatomically widespread distribution of high levels of BDNF in the spinal cord can induce unwanted side effects such as neuropathic pain, hyperreflexia, and abnormal limb motor function that prevent its therapeutic use (Boyce and Mendell, 2014). Furthermore, clinical trials for nervous system diseases using systemic delivery of various neurotrophic factors have been associated with both side effects and lack of therapeutic efficacy (Miller et al., 1996). To address these important issues, we have developed a biocompatible drug delivery system in the form of a hydrogel loaded with polysaccharide-BDNF particles self-assembled by electrostatic interactions. We have used this biomaterial-based platform to locally deliver BDNF to the injured cervical spinal cord with controlled duration to effectively repair rVRG–PhMN–diaphragm circuitry and consequently rescue diaphragmatic respiratory function with minimized side effects.

Materials and Methods

Animals. Female Sprague Dawley rats weighing 250–300 g were purchased from Taconic Farms. All animals were housed in a humidity-, temperature-, and light-controlled animal facility with ad libitum access to water and food. All experimental procedures were performed in compliance with protocols approved by the Thomas Jefferson University Institutional Animal Care and Use Committee (IACUC) and the Drexel University IACUC, as well as in accordance with the Society for Neuroscience “Policies on the Use of Animals and Humans in Neuroscience Research.”

Unilateral cervical contusion model. We used only female rats as we extensively optimized and comprehensively characterized the unilateral cervical contusion SCI model both functionally and histologically in female rats in our previous work (Nicaise et al., 2012, 2013). This contusion paradigm results in robust secondary PhMN degeneration, interruption of descending axonal populations that innervate the PhMN pool, and persistent diaphragm dysfunction. Briefly, cervical contusion was performed on the right side of spinal cord. Rats were deeply anesthetized with an intraperitoneal injection of a cocktail of ketamine (100 mg/kg), xylazine (5 mg/kg), and acepromazine (2 mg/kg). The cervical dorsal skin and underlying muscles were incised. The paravertebral muscles overlying C4–C5 were removed. At level C4/C5, rats were then subjected to a contusion using the Infinite Horizon Spinal Impactor (Precision Systems and Instrumentation) using a 1.5 mm tip at a force of 395 kdyn.

*G.B. and Z.W. contributed equally to this work.

The authors declare no competing financial interests.

Correspondence should be addressed to either of the following: Dr. Angelo C. Lepore, Department of Neuroscience, Vickie and Jack Farber Institute for Neuroscience, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, E-mail: angelo.lepore@jefferson.edu; or Dr. Yinghui Zhong, School of Biomedical Engineering, Science and Health Systems, Drexel University, Bossone 7-716, 3141 Chestnut Street, Philadelphia, PA 19104, E-mail: yz348@drexel.edu.

DOI: 10.1523/JNEUROSCI.3386-17.2018

Copyright © 2018 the authors. 0270-6474/18/385983-14$15.00/0
**Formulation and administration of hydrogels.** Dextran sulfate (DS; Sigma-Aldrich) and BDNF (PeproTech) were dissolved in deionized water at final concentrations of 4 and 0.8 mg/ml, respectively. The 4 mg/ml chitosan (CH) solution was prepared in 0.6% (v/v) acetic acid. Ten microliters of DS and BDNF solution was then mixed with 4 mg/ml CH in equal volume to form self-assembled DS–CH–BDNF complexes (particles). After centrifugation at 10,000 rpm for 10 min to remove supernatant, the complexes were loaded in 20 μl of 1.5% (w/v) agarose hydrogel. Immediately after the contusion SCI, 20 μl of agarose hydrogel loaded with DS–CH–BDNF complexes was administered into the intrathecal space at the injury site. Another 100 μl of blank agarose hydrogel was applied epidurally to protect the injury site.

**Characterization of BDNF release.** To measure BDNF release, rhodamine labeled neurons were conjugated to BDNF following a protocol provided by the Pierce Rhodamine Protein Labeling Kit (Thermo Fisher Scientific). A mixture of equal amounts of rhodamine-BDNF and BDNF was used to fabricate the drug delivery system following the procedures described above. Agarose hydrogel loaded with DS–CH–BDNF particles was incubated in HBSS, pH 7.4, at 37°C for quantification of BDNF release. The release media were changed every 24 h. The amount of BDNF released every 24 h was quantified by measuring at an excitation wavelength of 552 nm and an emission wavelength of 575 nm.

**Bioactivity of released BDNF.** Rat cortical neurons were used to assess the bioactivity of released BDNF. The cortices were isolated from embryonic day 17 rat embryos in accordance with protocols approved by the Drexel University IACUC. Dissociated cortical cells were seeded at a density of 120,000 cells/cm² and maintained in Neurobasal medium supplemented with 2% B27 supplement and 2 mM glutamine. After 7 d, B27 supplement in the culture medium was replaced by B27 minus antioxidants (AOs) to remove the neuroprotective AOs from the culture medium. The neurons were then treated with 100 μM hydrogen peroxide (H₂O₂); 100 μM H₂O₂ supplemented with equal amounts of fresh BDNF and rhodamine-BDNF at a total concentration of 30 ng/ml, with or without 120 ng/ml anti-BDNF blocking antibody (PeproTech); 100 μM H₂O₂ supplemented with BDNF released during a 24 h period on day 17 (containing a mixture of BDNF and rhodamine-BDNF, which was diluted to 30 ng/ml), with or without 120 ng/ml anti-BDNF blocking antibody; or 100 μM H₂O₂ supplemented with release medium from hydrogel loaded with DS–CH particles without BDNF. Untreated neurons were used as a negative control. After 6 h, cell viability was quantified using the alamarBlue cell viability assay. The cells were then stained with 2 μM Calcein AM (live staining) and imaged with an inverted fluorescence microscope (Leica).

**Diaphragm compound muscle action potential measurements.** Rats were anesthetized with isoflurane at a concentration of 2.0–2.5%. Phrenic nerve conduction studies were performed with single stimulation (0.5 ms duration; 6 mV amplitude) at the neck (either ipsilateral or contralateral to the contusion site) close to the passage of the phrenic nerve (Lepore et al., 2010; Li et al., 2014), and a ground needle electrode was inserted into the tail. A reference electrode was placed in the right abdominal region subcutaneously. Reproducibility was ensured by recording 10–20 times with a 5 s interval between stimulations. Recording was obtained via a surface strip along the costal margin of the diaphragm, and compound muscle action potential (CMAP) amplitude was measured from baseline to peak. Recordings were averaged over a 2 min time frame for each animal, and peak amplitude, burst duration, and frequency were measured. Using LabChart 7 software (ADInstruments; RRID:SCR_001620), the EMG signal was amplified and filtered through a bandpass filter (50–3000 Hz). EMG recordings were conducted once per animal immediately before the animal was killed.

**Retrograde labeling of PhMNs in cervical spinal cord.** Two weeks before the animal was killed, cholera toxin B subunit (CTB) conjugated to Alexa Fluor 647 (Life Technologies) was injected unilaterally into the intrathecal space of the ipsilateral hemidiaphragm under anesthesia (Nicaise et al., 2012; Li et al., 2014). This procedure was conducted to specifically label PhMN somato-dendrites in the ventral horn of the cervical spinal cord. In brief, following laparotomy, 15 μl of CTB (0.2% solution in distilled water) was intraperitoneally delivered transdiaphragmatically (3 injections of 5 μl each) using a 20 μl Hamilton syringe. Abdominal muscles and skin were then sutured separately.

**Perfusion and spinal cord dissection.** Animals were killed with a mixture of ketamine (300 mg/kg), xylazine (15 mg/kg), and acepromazine (6 mg/kg). After the hemidiaphragm was dissected, the animals were perfused using 0.9% saline solution, followed by 4% paraformaldehyde solution. Spinal cord and brain were then removed and postfixed in a 4% paraformaldehyde solution overnight at 4°C. After cryoprotection in 30% sucrose for ~3 d, cervical spinal cords were embedded in tissue-freezing medium and then frozen in dry ice. Spinal cord sections were cut (in both transverse and sagittal orientations) at a thickness of 20 μm.

**Assessment of lesion volume and ventral horn motor neurons.** Transverse spinal cord sections 160 μm apart were stained with cresyl violet for Nissl bodies and Erichrome cyanine for myelin. The lesion area on each section was quantified using Image software (RRID:SCR_003070) to calculate the total lesion volume. Motor neurons were outlined in Nissl myelin-stained sections in the cervical spinal cord ventral horn. Motor neuron cell bodies with a clearly identifiable nucleus and a soma of ~200 μm² were counted in a blinded manner (Lepore et al., 2011). PhMNs in the C3–C5 ventral horn specifically labeled with CTB were also counted in transverse sections spaced 160 μm apart in a blinded manner.

**Neuromuscular junction staining.** Fresh hemidiaphragm was dissected before perfusion for whole-mount immunohistochemistry (Wright et al., 2007; Li et al., 2014). Briefly, muscle was stretched, pinned down to Sylgard medium (Thermo Fisher Scientific), and extensively cleaned to remove any connective tissue to allow for antibody penetration. Motor axons and their terminals were labeled with primary antibodies SMI-312R (Covance; RRID:AB_2314906) and SV2-s (Developmental Studies Hybridoma Bank at the University of Iowa, Iowa City, IA; RRID: AB_2315387), respectively, and both antibodies were detected with FITC anti-mouse IgG secondary (Jackson ImmunoResearch). Postsynaptic acetycholine receptors were labeled with rhodamine-conjugated α-bungarotoxin (Life Technologies). Diaphragms were then mounted with VECTASHIELD mounting medium (Vector Laboratories), coverslipped, and stored at ~20°C. Labeled muscles were then analyzed for muscular nerve cell bodies with a clearly identifiable nucleus and a soma of ~200 μm² were counted in a blinded manner (Lepore et al., 2011). PhMNs in the C3–C5 ventral horn specifically labeled with CTB were also counted in transverse sections spaced 160 μm apart in a blinded manner.

**Immunohistochemistry.** Frozen transverse spinal cord sections were air dried, washed, and finally permeabilized with 0.4% Triton X-100 in PBS for 5 min at room temperature. For immunohistochemistry of 5-HT and the presynaptic marker Synaptophysin, samples were incubated in blocking solution (PBS containing 5% normal goat serum, 1% Triton X-100, and 0.05% Tween 20) for 2 h at room temperature. Sections were labeled overnight at 4°C with mouse synaptophysin antibody (1:250; Abcam; RRID:AB_2198854), and rabbit 5-HT antibody (1:15,000; Immunostar; RRID:AB_572263) in blocking solution. Sections were then washed three times with PBS (5 min/wash) and incubated with Alexa Fluor 405 goat-antibody (1:200; Abcam) and Alexa Fluor 488 goat-anti-rabbit (1:200; Jackson ImmunoResearch) in blocking solution for 2 h at room temperature. After washing three times with PBS (5 min/wash), sections were coverslipped. Images were acquired with a Zeiss Imager M2 Upright Microscope on a Fluoview FV1000 Confocal Microscope (Olympus), and MetaMorph software (Molecular Devices; RRID:SCR_002368) was used for quantification.
Quantification of 5-HT immunohistochemistry. For quantitative analysis of 5-HT immunostaining (see Fig. 9), we used the same image acquisition parameters for all samples, including excitation light intensity, camera settings, and exposure time. In transverse sections, we created concentric circles of increasing radii of 50 μm measured from the CTB-PhMN location. We quantified the number of 5-HT axon profiles, total 5-HT axonal length, and integrated intensity of 5-HT immunolabeling at each distance (0–50, 50–100, and 100–150 μm). For quantification of putative synaptic contacts between 5-HT+/synaptophysin+ terminals and CTB-labeled PhMNs, we considered those contacts within 2.5 μm of the surface of the CTB+ PhMN in single-z confocal images, based on previous work (Kinkead et al., 1998; Issa et al., 2010).

Experimental design and statistical analysis. In the Results section, we provide details of group means, SEM, statistical tests used, and results of statistical analyses (including the exact p value) for each experiment.

We gave careful thought to minimizing animal numbers. To conduct an a priori power analysis (with SigmaPlot 12) for studies involving in vivo diaphragm functional analysis, spinal cord histology, spinal cord immunohistochemistry, and whole-mount muscle labeling, we used previously obtained values (i.e., EMG and CMAP recordings, lesion size analysis, motor neuron counts, CTB labeling, NMJ morphology assessment, and 5-HT axon quantification) from our laboratories for rats subdurally implanted with DS–CH–BDNF complexes for >17 d. Inset depicts release profile from 3 to 17 d, n = 3/group.

Results

Bioactive BDNF was released from agarose hydrogel loaded with DS–CH–BDNF complexes for >17 d. In this study, we found that negatively charged DS could form self-assembled complexes (particles) with positively charged CH and BDNF possibly through electrostatic interaction. We embedded these particles in agarose hydrogel so that they can remain localized at the injury site in vivo. Relatively high amounts of BDNF were released from BDNF-loaded hydrogel in vivo in the first 2 d, followed by low-dose release (364.2–29.5 ng/d) for >17 d (Fig. 1). We further investigated whether this novel drug delivery system is capable of maintaining the bioactivity of encapsulated BDNF. H2O2-induced massive loss of cortical neurons in vitro (18.29 ± 0.80% viability vs 100 ± 2.23% for untreated control; Fig. 2A, B), whereas fresh BDNF (38.94 ± 1.38%; Fig. 2D) or BDNF released from the hydrogel on day 17 (38.36 ± 1.13%; Fig. 2E) diluted to the same concentration as fresh BDNF) improved neuron survival (F(6,114) = 427.1, Tukey’s post-test; H2O2 vs fresh BDNF, p < 0.0001; H2O2 vs released BDNF, p < 0.0001; released without BDNF vs fresh BDNF, p < 0.0001; released without BDNF vs released BDNF, p < 0.0001; ANOVA; n = 3/group). Anti-BDNF antibody completely blocked the neuroprotective effect of both fresh (18.76 ± 1.13%; Fig. 2F) and hydrogel-released (17.53 ± 0.47%; Fig. 2G) BDNF (F(6,114) = 427.1, Tukey’s post-test; fresh BDNF vs fresh BDNF + Ab, p < 0.0001; released BDNF vs released BDNF + Ab, p < 0.0001; ANOVA; n = 3/group), suggesting both that the neuroprotective effect was from BDNF and that this drug delivery system itself was not neuroprotective. Quantitative cell viability assessment confirmed that both fresh and hydrogel-released BDNF significantly inhibited H2O2-induced neurotoxicity (Fig. 2H). Moreover, there was no significant difference in cell viability between neuronal cultures treated with fresh and hydrogel-released BDNF, suggesting that the polysaccharide-based BDNF delivery system maintained the activity of BDNF for at least 17 d. In addition, release medium from agarose hydrogel loaded with DS–CH particles without BDNF showed no neuroprotective or neurotoxic effect (17.53 ± 0.47%; Fig. 2C); this result is consistent with that of the anti-BDNF antibody blocking test and confirms the safety of this drug delivery system.

BDNF hydrogel implantation significantly improved diaphragm function following cervical contusion SCI

In a rat model of unilateral C4/C5 contusion SCI, we subdurally implanted BDNF hydrogel or blank hydrogel control at the level of the contusion immediately postinjury. We tested the in vivo effects of hydrogel implantation on diaphragmatic respiratory function by quantifiably measuring both inspiratory EMGs and evoked CMAPs in anesthetized rats.

We assessed EMG burst amplitude as a measure of rhythmic diaphragm activation under normal eupnic breathing conditions. We conducted intradiaphragm EMG recordings separately from ventral, medial, and dorsal subregions of the hemidiaphragm ipsilateral to the contusion. We and others have previously shown that each diaphragm subregion is innervated by PhMNs whose cell bodies are located at different rostral–caudal

Figure 1. BDNF was released from hydrogel loaded with DS–CH–BDNF complexes for >17 d. Inset depicts release profile from 3 to 17 d, n = 3/group.
portions of the C3-C5 spinal cord (Li et al., 2015). In contusion animals implanted with blank hydrogel, we observed the largest loss of EMG amplitude in the dorsal subregion of the muscle (1.7 ± 0.34 vs 8.16 ± 0.83 mV/s for the intact contralateral hemidiaphragm; Fig. 3A, C), which is primarily innervated by the most caudal portion of the PhMN pool. Importantly, we performed the contusion at C4/C5, demonstrating that the portion of the PhMN pool most severely affected by the injury matched the subregion of the hemidiaphragm with the lowest EMG amplitudes. EMG amplitudes in the ventral and medial subregions of the muscle were not as severely reduced compared with EMG amplitudes obtained from these same subregions in the control uninjured condition (Fig. 3C), particularly in the ventral subregion, which is primarily innervated by the most rostrally located PhMNs (i.e., on the opposite end from the contusion). In addition, BDNF showed no effect on EMG amplitudes at these ventral (blank gel, 4.89 ± 0.70 mV/s; BDNF, 4.59 ± 0.34 mV/s) and medial (blank gel, 2.96 ± 1.10 mV/s; BDNF, 3.04 ± 0.13 mV/s) hemidiaphragm locations compared with blank hydrogel control ($F_{(6,21)} = 10.47$; Tukey’s post-test; ventral: blank vs BDNF, $p = 0.9$; medial: blank vs BDNF, $p = 0.9$; contralateral vs ventral/blank, $p = 0.06$; contralateral vs ventral/BDNF, $p = 0.06$; contralateral vs medial/blank, $p = 0.0004$; contralateral vs medial/BDNF, $p = 0.0015$; ANOVA; $n = 4$ rats/group; Fig. 3C). Compared with blank hydrogel-implanted animals (Fig. 3A), BDNF hydrogel resulted in significantly greater diaphragm EMG amplitudes in the dorsal subregion (blank gel, 1.4 ± 0.42 mV/s; BDNF, 5.02 ± 0.41 mV/s) at 5 weeks post-SCI ($F_{(6,21)} = 10.47$; Tukey’s post-test; dorsal: blank vs BDNF, $p = 0.04$; contralateral vs dorsal/blank, $p < 0.0001$; contralateral vs dorsal/BDNF, $p = 0.053$; ANOVA; $n = 4$ rats/group; Fig. 3B, C). No differences were noted in burst frequency (dorsal subregion: blank gel, 34.72 ± 2.39 bursts/min; BDNF, 32 ± 6.81 bursts/min; $F_{(5,14)} = 1.05$; Tukey’s post-test; ventral: blank vs BDNF, $p = 0.9$; medial: blank vs BDNF, $p = 0.92$; dorsal: blank vs BDNF, $p = 0.9$; ANOVA; $n = 4$ rats/group; Fig. 3D) or burst duration (dorsal subregion: blank gel, 0.50 ± 0.06 s; BDNF, 0.61 ± 0.45 s; $F_{(5,14)} = 1.87$, Tukey’s post-test; ventral: blank vs BDNF, $p = 0.59$; medial: blank vs BDNF, $p = 0.90$; dorsal: blank vs BDNF, $p = 0.62$; ANOVA; $n = 4$ rats/group; Fig. 3E) between blank hydrogel and BDNF hydrogel groups at any diaphragm subregion, and these burst frequency and duration values in hydrogel-implanted contusion rats were similar to those in uninjured control animals that we assessed in previous work (Li et al., 2015).

We also conducted CMAP recordings from the ipsilateral hemidiaphragm in response to supramaximal phrenic nerve stimulation. Unlike spontaneous EMG recordings, this technique allowed us to selectively quantify functional innervation of the diaphragm by PhMNs independent of the contribution of the descending bulbospinal drive. Unlike with EMGs in which we insert small needle electrodes into specific subregions of the muscle, we recorded CMAP amplitudes from the entire hemidiaphragm simultaneously using a surface electrode. We obtained CMAP recordings separately from both the ipsilateral and contralateral hemidiaphragm (Fig. 4A). Starting at 2 weeks postcon-
4.37 ± 0.42 mV; week 2, 3.92 ± 0.33 mV; week 3, 3.58 ± 0.27 mV; $F_{(7,24)} = 11.64$, Tukey’s post-test; blank vs BDNF: week 1, $p = 0.15$; week 2, $p = 0.001$; week 3, $p < 0.0001$, ANOVA; $n = 4$ rats/group; Fig. 4B). Furthermore, CMAP amplitudes obtained from the ipsilateral hemidiaphragm of blank hydrogel animals were significantly reduced at all time points compared with the intact contralateral hemidiaphragm of the same animals (blank gel, 6.13 ± 0.27 mV), while BDNF hydrogel rescued CMAP amplitudes in ipsilateral hemidiaphragm compared with the within-animal intact contralateral hemidiaphragm (BDNF, 5.82 ± 0.3 mV; Fig. 4B).

Collectively, these electrophysiological findings using two powerful in vivo assessments of muscle activation demonstrate that implantation of BDNF hydrogel locally at the site of cervical contusion SCI robustly and persistently preserved diaphragm function.

**BDNF hydrogel did not decrease lesion size, lesion volume, or cervical motor neuron cell body degeneration following cervical contusion SCI**

To determine whether BDNF hydrogel improved diaphragmatic respiratory function after C4/C5 contusion via a central neuroprotective effect within the cervical spinal cord, we quantified both lesion size and sparing of ventral horn motor neurons. In cresyl violet-stained transverse sections of the cervical spinal cord
at 5 weeks postcontusion, we found that BDNF hydrogel (Fig. 5B) did not reduce lesion size compared with blank hydrogel control (Fig. 5A) at all rostral–caudal distances from the lesion epicenter (Fig. 5C; \( p > 0.05 \) at all distances, ANOVA; \( n = 5 \) group). Furthermore, BDNF hydrogel did not reduce overall lesion volume compared with blank hydrogel-implanted animals, as determined with the Cavalieri estimator of volume (blank, 5.93 ± 0.23 mm\(^3\); BDNF, 5.11 ± 0.34 mm\(^3\); \( F_{(3,16)} = 44.42 \), Tukey’s post-test; \( p = 0.54 \), ANOVA; \( n = 5 \) rats/group). In these same cresyl violet-stained sections from the cervical spinal cord, we found that BDNF hydrogel (Fig. 6B) also did not attenuate loss of ventral horn motor neurons located ipsilateral to the contusion compared with blank hydrogel control (Fig. 6A) at 5 weeks post-SCI. Specifically, we observed no effect of BDNF hydrogel on motor neuron counts that included all α motor neuron populations (not just PhMNs), both at defined rostral–caudal distances from the lesion epicenter (\( p > 0.05 \) at all distances, ANOVA; \( n = 5 \) group; Fig. 6C) and across the entire cervical enlargement (blank gel, 4382 ± 289 motor neurons/animal; BDNF, 4603 ± 362 motor neurons/animal; \( F_{(3,16)} = 10.22 \), Tukey’s post-test; \( p = 0.90 \), ANOVA; \( n = 5 \) rats/group; Fig. 6D). BDNF also had no effects on motor neuron counts on the contralateral side (blank gel, 9724 ± 827 motor neurons/animal; BDNF, 10,406 ± 788 motor neurons/animal; \( F_{(3,16)} = 10.22 \), Tukey’s post-test; \( p = 0.22 \), ANOVA; \( n = 5 \) rats/group). Together, these histological findings suggest that the therapeutic mechanism of action of BDNF hydrogel was not central neuroprotection within the injured cervical spinal cord.

BDNF hydrogel significantly enhanced PhMN innervation of the diaphragm

Though BDNF hydrogel did not reduce secondary degeneration within the cervical spinal cord as assessed by lesion size and motor neuron somal counts, BDNF may have instead acted in a protective manner to maintain peripheral innervation at the diaphragm NMJ, the synapse that is critical for PhMN–diaphragm connectivity. To address this possibility, we selectively labeled PhMN cell bodies by intrapleurally injecting the retrograde axonal tracer, Alexa Fluor 647-conjugated CTB, into the ipsilateral hemidiaphragm. Importantly, we performed these CTB injections at 4 weeks postinjury/treatment to assess muscle innervation, because (1) PhMN soma will only be labeled with CTB following intrapleural injection if NMJ innervation is intact and (2) secondary PhMN loss is complete by this late injection time point (Nicaise et al., 2013). In sagittal sections of the spinal cord, CTB labeled a relatively compact column of PhMNs that extended from C3 to C5 (Fig. 7C). In transverse sections, we found CTB-labeled cells in the ipsilateral ventral horn at levels C3–C5 (Fig. 7C). Compared with uninjured rats (252.7 ± 13.38 PhMNs), both blank hydrogel-implanted (61.67 ± 8.82 PhMNs) and BDNF hydrogel-implanted (156.7 ± 20.28 PhMNs) contusion animals showed reduced numbers of retrogradely labeled PhMNs (\( F_{(2,6)} = 40.96 \), Tukey’s post-test; intact vs blank gel, \( p = 0.004 \); intact vs BDNF, \( p = 0.0093 \); ANOVA; \( n = 3 \) rats/group). However, there were significantly greater numbers of CTB-labeled PhMNs in the C3–C5 spinal cord of BDNF hydrogel animals compared with blank hydrogel controls (\( F_{(2,6)} = 40.96 \), Tukey’s post-test; \( p = 0.0097 \), ANOVA; Fig. 7D). Given the absence of motor neuron soma protection, these data suggest that BDNF hydrogel robustly preserved diaphragm innervation by PhMNs.
These findings show that BDNF delivered locally to the cervical spinal cord can exert important therapeutic effects on PhMNs spared the injury independent of overt somal protection. Along these lines, BDNF hydrogel implantation also significantly reduced cell body atrophy of CTB-labeled PhMNs (intact, 678.27 ± 27.84 μm²; blank gel, 496.47 ± 27.74 μm²; BDNF, 680.60 ± 23.78 μm²; F(2,111) = 15.84, Tukey’s post-test; intact vs blank gel, p < 0.0001; blank gel vs BDNF, p < 0.0001; intact vs BDNF, p = 0.9; ANOVA; n = 38 neurons/group; Fig. 7E), suggesting that BDNF may be able to improve the health of PhMNs after cervical SCI.

To more definitively assess the effects of BDNF hydrogel on diaphragm NMJ innervation, we performed detailed confocal morphological analysis of individual NMJ phenotypes in the...
hemidiaphragm ipsilateral to the contusion, including separately at dorsal, medial, and ventral subregions (Wright and Son, 2007; Wright et al., 2007, 2009). At 5 weeks postcontusion, we performed whole-mount immunohistochemistry on hemidiaphragm by labeling phrenic motor axons all the way to their terminals with neurofilament (SMI-312) and SV2 antibodies. We also labeled postsynaptic nicotinic acetylcholine receptors in the muscle with Alexa Fluor 555-conjugated α-bungarotoxin. A–E. Compared with blank hydrogel (A), BDNF hydrogel (B) significantly increased the percentage of fully innervated NMJs (C), as well as decreased the percentage of both partially denervated (D) and completely denervated (E) NMJs. C–E, BDNF hydrogel implantation robustly preserved NMJ innervation at the dorsal subregion, but also exerted a more modest therapeutic effect on innervation at the medial subregion. We characterized individual NMJs as follows: intact (I.); fully denervated (F.D.); partially denervated (P.D.). Scale bar, 50 μm. We expressed results as the mean ± SEM. *p < 0.05.
not conducted this analysis of contralateral muscle again in the current study.

Collectively, these findings with retrograde labeling and NMJ morphology analysis (along with CMAPs) demonstrate for the first time that BDNF significantly enhanced diaphragm NMJ innervation by PhMNs after SCI.

BDNF hydrogel implantation following cervical contusion enhanced serotonicergic innervation of PhMNs

BDNF may have also exerted therapeutic effects on respiratory neural circuitry via mechanisms in addition to enhanced NMJ innervation. Descending serotonergic input plays an important role in regulating the excitability of spinal cord motor neurons, in particular their response to glutamatergic signaling (Perrier et al., 2013). It has been reported that BDNF-expressing mesenchymal stem cells significantly increased 5-HT fiber growth after SCI (Sasaki et al., 2009). Therefore, in the context of diaphragm function, BDNF may be able to strengthen rhythmic excitatory input to PhMNs from spared and/or regrowing rVRG axons by increasing serotonergic innervation of PhMNs via 5-HT fiber sprouting. To address this possibility, we quantified 5-HT immunostaining in the C3-C5 ventral horn ipsilateral to the contusion to 5 weeks postcontusion. Compared with blank hydrogel control (Fig. 9A, C), we found that BDNF hydrogel (Fig. 9B, D) enhanced the density of serotonergic axons directly surrounding CTB-labeled PhMNs.

We extended this analysis of 5-HT fiber growth within the PhMN pool by performing quantification of (1) numbers of 5-HT⁺ axon profiles, (2) length of these 5-HT⁺ axon profiles, and (3) integrated intensity of 5-HT immunostaining at multiple defined distances from CTB-labeled PhMNs in transverse sections (Fig. 9E, F). We present each of these datasets at three separate distances from PhMNs to show the proximity effects of BDNF hydrogel on 5-HT axonal growth responses with respect to the location of PhMNs. Compared with blank hydrogel control, BDNF increased the number of 5-HT⁺ axonal profiles at all three distances \( (F_{5,30} = 27.55, \text{Tukey’s post-test; } 0–50 \mu\text{m: blank = 49.83 } \pm 5.84; \text{BDNF = 100 } \pm 7.35; p = 0.04; 50–100 \mu\text{m: blank = 111.6 } \pm 6.0; \text{BDNF = 162.50 } \pm 7.61; p = 0.03; 100–150 \mu\text{m: blank = 135.83 } \pm 10.68; \text{BDNF = 223.33 } \pm 21.55; p < 0.0001, \text{ANOVA; } n = 3 \text{ rats/group; Fig. 9G}). \) BDNF also increased total 5-HT⁺ axonal length at all three distances \( (F_{5,30} = 76.80, \text{Tukey’s post-test; } 0–50 \mu\text{m: blank = 272.72 } \pm 20.01 \mu\text{m; BDNF = 712.17 } \pm 37.91; p < 0.0001; 50–100 \mu\text{m: blank = 776.47 } \pm 63.94; \text{BDNF = 1253.12 } \pm 34.54; p < 0.0001; 100–150 \mu\text{m: blank = 901.11 } \pm 40.24; \text{BDNF = 1565.89 } \pm 84.01; p < 0.0001, \text{ANOVA; } n = 3 \text{ rats/group; Fig. 9H}). \) In addition, BDNF increased integrated intensity of 5-HT immunostaining compared with blank hydrogel \( (F_{5,30} = 78.08, \text{Tukey’s post-test; } 0–50 \mu\text{m: blank = 0.74 } \pm 0.08 \text{ a.u.; BDNF = 1.91 } \pm 0.10 \text{ a.u.; } p = 0.04; 50–100 \mu\text{m: blank = 3.49 } \pm 0.14 \text{ a.u.; BDNF = 4.88 } \pm 0.29 \text{ a.u.; } p = 0.009; 100–150 \mu\text{m: blank = 5.16 } \pm 0.23 \text{ a.u.; BDNF = 7.14 } \pm 0.49 \text{ a.u.; } p = 0.0001, \text{ANOVA; } n = 3 \text{ rats/group; Fig. 9I}). \)

Last, we conducted quantitative analysis of synaptic input to PhMNs by serotonergic axons using multilabeling immunohistochemistry for 5-HT⁺ axons, CTB⁺ postsynaptic PhMNs, and the presynaptic marker synaptophysin. We assessed the number of putative synaptic contacts between 5-HT fibers and CTB-labeled PhMNs using confocal acquisition of z-stacks and quantification of 5-HT axon–PhMN contacts using single-z section analysis to establish direct apposition of presynaptic 5-HT⁺/synaptophysin⁺ axon terminals and postsynaptic CTB⁺ PhMNs. Compared with blank hydrogel control (Fig. 10A) and BDNF hydrogel (Fig. 10B) animals showed significantly more putative synaptic contacts between 5-HT axons and PhMNs (blank gel, 1.6 ± 0.29/PhMN soma; BDNF, 5.2 ± 0.35; \( t = 7.86; df = 28; p < 0.0001, \text{unpaired } t\text{-test; } n = 4 \text{ rats/group; Fig. 10C}). \)

Collectively, these results show that BDNF hydrogel promoted plasticity of axonal populations associated with enhanced PhMN excitability. This represents an additional mechanism potentially responsible for functional recovery, particularly the increased EMG amplitudes that may be associated with rhythmic drive to PhMNs from supraspinal respiratory centers.

Discussion

Novel biomaterial-based strategy for SCI repair

As a viable drug delivery system for BDNF therapeutics, we have developed a hydrogel loaded with BDNF. All of the materials used in this delivery platform are biocompatible natural poly-saccharides that have been shown to be safe for human use (Komai et al., 2005; Scarano et al., 2009; Neimat-Andersson et al., 2014). The BDNF-loaded hydrogel can be implanted subdurally for local BDNF delivery at the injury site without damaging spinal cord tissue. Collectively, the hydrogel could be implanted, for example, when spine decompression/stabilization surgery is performed so that no additional surgery will be required for hydrogel administration.

Our innovative approach is significant for developing a therapy for respiratory dysfunction after SCI because we are harnessing the power of biomaterial design to address both biological considerations (i.e., the delivery of specific therapeutic factors to target relevant pathogenic mechanisms) and practical issues (i.e., local delivery to the injury site with appropriate dosing and duration). We found that BDNF exerted effects on peripheral mechanisms such as enhanced NMJ innervation and central reparative processes such as stimulating 5-HT axonal growth.

Our BDNF hydrogel releases relatively high amounts of BDNF in the first 2 d, followed by low-dose release (364.2–29.5 ng/d) for >17 d. While the formulation we assessed was functionally and histopathologically efficacious, the optimal dose and duration of BDNF treatment for cervical SCI remain unknown. Furthermore, persistently high levels of BDNF within the spinal cord can result in unwanted side effects such as neuropathic pain, hyperreflexia, and abnormal motor function (Boynce and Mendell, 2014). Therefore, it will be important in future work to test additional release profiles to identify the most effective treatment paradigm with minimized side effects.

Local delivery of BDNF hydrogel is a clinically viable approach for reducing secondary damage to respiratory circuitry following SCI

Despite a body of work showing the neuroprotective effects of BDNF after axotomy, in SCI models, and in degenerative diseases such as ALS (Weishaupt et al., 2012), our data do not show protective effects on cervical motor neuron survival or lesion size. Instead, our results shed light on an incredibly important outcome of secondary injury that has not received extensive attention: peripheral muscle denervation by the axon terminals of motor neurons spared by the injury. Even though the cell bodies of these neurons persist, the circuit is incomplete. BDNF signaling through TrkB normally acts to maintain diaphragm NMJ structure and PhMN innervation in intact/non-SCI conditions (Mantilla et al., 2014b; Greising et al., 2015); BDNF hydrogel delivery in our model may represent an extension of this important function in the injured setting. These data with BDNF hydrogel implantation demonstrate the therapeutic benefits of this approach for the respiratory system post-SCI.
Figure 9. BDNF hydrogel implantation following cervical contusion enhanced serotonergic innervation of PhMNs. We quantified 5-HT immunostaining in the C3–C5 ventral horn ipsilateral to the contusion at 5 weeks postinjury. A–D. Compared with blank hydrogel control (A, C), BDNF hydrogel (B, D) enhanced the density of serotonergic axons surrounding CTB-labeled PhMNs at 5 weeks postcontusion. E–I. Compared with blank hydrogel control (E), BDNF (F) increased the number of 5-HT axonal profiles (G), total 5-HT axonal length (H), and integrated intensity of 5-HT immunostaining (I) at multiple defined distances from CTB-labeled PhMNs. Scale bars: A, B, E, F, 50 μm; C, D, 100 μm. We expressed results as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
power of addressing muscle denervation that underlies persistent diaphragm paralysis.

Our NMJ morphology data are only from a single late time point, raising the possibility that, instead of acting via initial preservation of NMJ innervation, BDNF hydrogel promoted NMJ reinervation following initial denervation (or a combination of both). It is challenging to distinguish between an NMJ that was never denervated and one that was denervated and subsequently reinnervated as reinnervated NMJs often appear morphologically normal by this late time point postinjury. However, we observed CMAP preservation starting at the relatively early time of 2 weeks post-SCI, supporting the contention that BDNF hydrogel was acting to prevent initial denervation at diaphragm NMJ. Furthermore, we did not observe any hallmarks of peripheral plasticity at the NMJ with BDNF hydrogel such as terminal sprouting, nodal sprouting, or regrowth of initially retracted phrenic motor axons, though we also performed this assessment at a late time point long after BDNF stopped being released from the hydrogel. On the other hand, although the effects of BDNF hydrogel on 5-HT axonal growth around the CTB-labeled PhMNs could be due to initial preservation instead of sprouting, we observed increased 5-HT fiber density with BDNF hydrogel rostral to the contusion at locations where secondary degeneration is not significant, suggesting that BDNF is promoting the growth of these axons and not sparing.

**BDNF hydrogel may also be acting via various reparative mechanisms**

Given the clinical relevance of delayed intervention in the SCI patient population, it will be important in future work to test hydrogel implantation at time points beyond the window of early secondary degeneration. Reparative effects of interventions such as BDNF delivery may be viable targets in this context, including the sprouting of spared motor axons and reinnervation of denervated endplates that is a potentially powerful substrate for promoting functional recovery. To this point, NMJ reinnervation is a mechanism by which functional recovery can occur after motor neuron injury, including spontaneously without therapeutic interventions. In our cervical contusion model, we previously demonstrated that partial loss of the PhMN pool is followed by sprouting and reinnervation of a portion of the denervated junctions, which was associated with progressive, spontaneous recovery of diaphragm function as assessed by CMAP amplitudes (though recovery was only minimal; Nicaise et al., 2013). BDNF hydrogel implantation may enhance this process of NMJ reinnervation. In addition to our data demonstrating morphological effects at the NMJ, previous work has also shown that BDNF can induce other changes at the diaphragm NMJ. For example, BDNF enhances synaptic transmission at the diaphragm NMJ (Martilla et al., 2004), including in the C2 hemisection model using intrapleural adeno-associated virus–BDNF injection (Gransee et al., 2013), suggesting additional peripheral mechanisms relevant to diaphragm recovery.

Other reparative mechanisms may also be influenced by BDNF delivered locally to the injured cervical spinal cord. For example, BDNF hydrogel may be capable of modulating PhMN properties such as intrinsic excitability and response to bulbospinal input (Gill et al., 2016). This strengthened synaptic input to PhMNs could be from the small number of ipsilateral rVRG axons spared by contusion and/or latent contralateral rVRG input that is mostly inactive before injury. BDNF can increase the excitability of spinal cord motor neurons involved in the control of limb function (Boyce et al., 2012; Boyce and Mendell, 2014). The relatively small amount of spontaneous diaphragm recovery that occurs after C2 hemisection SCI is mediated in part by BDNF acting upon TrkB receptors expressed by PhMNs (Mantilla et al., 2013, 2014a). Diaphragm activation by PhMNs can also be enhanced in C2 hemisection with intrathecal BDNF injection (Mantilla et al., 2013), intraspinal transplantation of mesenchymal stem cells engineered to overexpress BDNF (Gransee et al., 2015), and selective overexpression of TrkB in PhMNs (Gransee et al., 2013; Martínez-Gálvez et al., 2016). Using phrenic nerve recordings as a measure of PhMN output, BDNF has also been shown to play a key role in the plasticity of spared glutamatergic input to PhMNs that underlies the partial recovery of diaphragm function observed after cervical hemisection (Dale-Nagle et al., 2010). Given this body of work, it will be important moving forward to test the effects of our BDNF hydrogel on PhMN excitability, particularly at the single-cell level and in response to bulbospinal synaptic input.

We found that BDNF hydrogel did not improve EMG amplitude in the ventral and medial subregions of the hemidiaphragm, but only in the dorsal portion of the muscle. We hypothesize that the beneficial effect of BDNF hydrogel on EMG burst amplitudes in the dorsal hemidiaphragm may be due to the location of hydrogel implantation. Based on previous work from both our laboratory and others, it has been shown that different subregions of the hemidiaphragm are innervated by phrenic motor neurons located at different locations within the C3–C5 spinal cord (Li et al., 2015). In general, PhMNs whose soma are found at C3 primarily innervate the ventral portion of the muscle. PhMNs at the opposite end of the PhMN pool (C5) primarily innervate the

---

**Figure 10.** BDNF hydrogel implantation increased 5-HT+/synaptophysin+ presynaptic terminals at CTB+ PhMN soma. We assessed the number of putative synaptic connections between 5-HT fibers and CTB-labeled PhMNs using confocal acquisition of z-stacks and quantification of 5-HT axon-PhMN contacts using single-z-section analysis to establish the direct apposition of presynaptic 5-HT+/synaptophysin+ axon terminals and postsynaptic CTB+ PhMNs. **A–C**, Compared with blank hydrogel control (**A**), BDNF hydrogel (**B**) animals showed significantly more putative synaptic contacts between 5-HT axons and PhMNs (**C**). We expressed results as the mean ± SEM. Scale bar, 10 μm. ****p < 0.0001.
dorsal hemidiaphragm subregion, while those at C4 primarily innervate the medial part of the muscle. Our unilateral contusion injury is located at the C4/C5 level, which explains why the EMG burst amplitudes in blank-hydrogel control animals are lowest at the dorsal and medial subregions (particularly the dorsal subregion). We implanted the BDNF hydrogel (as well as the control blank hydrogel) directly above the contusion epicenter; therefore, we hypothesize that the local delivery of BDNF exerted effects close to the hydrogel implantation site, which may explain the selective effects in the dorsal hemidiaphragm.

BDNF hydrogel promoted serotonergic axon growth

BDNF acting through TrkB plays an important role in neuroplasticity following SCI, including the regeneration of axotomized neurons and the sprouting of spared fibers (Weishaupt et al., 2012). A number of previous studies has shown that BDNF treatment in SCI models increases the survival of neurons and axonal growth when delivered by intrathecal infusion (Bregman et al., 1997; Ye and Houle, 1997; Novikova et al., 2000, 2002), intraspinal viral transduction (Koda et al., 2004; Boyce et al., 2012), and stem/progenitor cell transplantation (Lu et al., 2005; Lysney et al., 2006). Along these lines, we observed robustly increased PhMN innervation by 5-HT axons in response to BDNF hydrogel, presumably via an axonal growth response (and not via sparing, as discussed above). BDNF hydrogel may have also restored diaphragm function in our cervical contusion model by promoting the regrowth of injured bulbospinal rVRG axons and synaptic reconnection with spared PhMNs. Furthermore, the generation of novel connections (that differ from the original preinjury circuitry) by growing axons can promote some degree of functional recovery post-SCI, either spontaneously (Bareyre et al., 2004) or in response to the manipulation of axonal growth inhibitors (Siegel et al., 2015). Accordingly, BDNF hydrogel may have resulted in reinnervation of PhMNs by sprouting contralateral rVRG axons spared by the injury. Supporting these possibilities, bulbospinal axon populations have repeatedly shown axon growth responses to BDNF (Weishaupt et al., 2012).

Conclusions

Our findings may have profound implications for SCI patients with persistent diaphragm dysfunction. We have developed a novel and safe biomaterial-based platform to locally deliver BDNF to the injured cervical spinal cord with controlled dosing and duration. Furthermore, in a clinically relevant animal model of cervical contusion SCI, we have successfully demonstrated the therapeutic efficacy of this promising drug delivery system for effectively repairing PhMN–diaphragm circuitry and maintaining diaphragmatic respiratory function. In addition, we demonstrate novel mechanisms by which local BDNF delivery to an SCI site can repair respiratory neural circuitry simultaneously at multiple neuroanatomical locations: enhanced diaphragm innervation peripherally at the NMJ and increased PhMN innervation by descending 5-HT axons centrally within the ventral horn of the cervical spinal cord.

References